Wegovy Approved for Broader Use in obesity Treatment, Expanding Access to Weight Loss Drug
Table of Contents
The Food and Drug Administration (FDA) has expanded the approval of wegovy, a popular weight-loss drug manufactured by Novo Nordisk, to include treatment for adults with a body mass index (BMI) of 27 or higher without requiring a diagnosis of obesity-related health conditions. https://www.fda.gov/news-events/press-announcements/fda-approves-wegovy-new-indication-adults-without-obesity This decision, announced in December 2023, considerably broadens the potential patient population for the drug, addressing a growing public health concern as over 40% of U.S.adults are living with obesity. https://www.cdc.gov/obesity/data/adult.html
What is Wegovy and How Does it Work?
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a natural hormone in the body that regulates appetite and food intake.Wegovy mimics this hormone, helping individuals feel fuller for longer and reducing cravings, ultimately leading to weight loss. https://www.mayoclinic.org/drugs-supplements/semaglutide-injection-route/description/drg-20488993 ItS administered as a weekly injection.
Previously, Wegovy was only approved for adults with a BMI of 30 or higher, or for those with a BMI of 27 or higher and at least one weight-related health condition like high blood pressure, type 2 diabetes, or cardiovascular disease. The expanded approval now includes individuals with a BMI of 27 or higher nonetheless of co-morbidities.
The Growing Obesity Epidemic and Demand for Treatment
Obesity is a major public health crisis,linked to numerous serious health problems including heart disease,stroke,type 2 diabetes,certain types of cancer,and a reduced quality of life.The CDC estimates that obesity-related medical costs in the U.S.reached nearly $173 billion in 2019.https://www.cdc.gov/obesity/data/costs.html
The demand for effective weight-loss treatments like Wegovy and its competitor, Eli Lilly’s Zepbound (also a GLP-1 receptor agonist), has surged. This demand has, at times, lead to supply shortages. https://www.reuters.com/business/healthcare-pharmaceutical/novo-nordisk-says-wegovy-supply-constraints-continue-2024-02-01/ Novo Nordisk is working to increase production capacity to meet the growing need.
Affordability and Access Concerns
Despite the expanded approval, the high cost of Wegovy remains a notable barrier to access for many. The list price is over $1,300 per month, although insurance coverage varies. https://www.goodrx.com/wegovy
The Trump administration previously negotiated lower prices for GLP-1 medicines. Under an agreement reached in November 2023, Novo Nordisk and eli Lilly committed to selling starter doses of their weight-loss pills, if approved, for $149 a month to Medicare and Medicaid patients and uninsured cash-paying customers. https://www.reuters.com/business/healthcare-pharmaceutical/us-negotiates-lower-prices-diabetes-obesity-drugs-2023-11-16/ These efforts aim to improve affordability and expand access to these potentially life-changing medications.
Key Takeaways:
* Expanded Approval: Wegovy is now approved for adults with a BMI of 27 or higher, regardless of other health conditions.
*